Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 5Not yet recruiting 3Suspended 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Specimen Handling 16Biopsy 11Magnetic Resonance Spectroscopy 10Taxes 4Bevacizumab 4Cyclophosphamide 3Cetuximab 3olaparib 2decitabine and cedazuridine drug combination 2Vincristine 2Prednisone 2Paclitaxel 2Immunoglobulin G 2Gemcitabine 2Doxorubicin 2Disulfides 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2(225)Ac-DOTA-c(RGDyK) 2zimberelimab 1zanubrutinib 1trastuzumab deruxtecan 1taletrectinib 1spartalizumab 1sotigalimab 1relatlimab 1regorafenib 1prednylidene 1neratinib 1mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Immunotherapy × 30 days × Clear all
NCT06130826 2026-06-03

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

City of Hope Medical Center

Phase 1 Suspended
24 enrolled
BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡